This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Regeneron (REGN)

Tipranks - Tipranks - Fri May 1, 7:08AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viking Therapeutics (VKTX), Regeneron (REGN) and Bausch + Lomb Corporation (BLCO) with bullish sentiments.

Claim 55% Off TipRanks

Viking Therapeutics (VKTX)

Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Viking Therapeutics today and set a price target of $100.00. The company’s shares closed last Wednesday at $31.33, close to its 52-week low of $24.41.

According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 10.9% and a 44.3% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, NewAmsterdam Pharma Company, and Apellis Pharmaceuticals. ;'>

Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $93.27, implying a 188.9% upside from current levels. In a report released today, BTIG also maintained a Buy rating on the stock with a $125.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Regeneron (REGN)

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Regeneron, with a price target of $796.00. The company’s shares closed last Wednesday at $686.36, close to its 52-week low of $629.02.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 16.8% and a 45.2% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

Currently, the analyst consensus on Regeneron is a Strong Buy with an average price target of $876.33, which is a 24.3% upside from current levels. In a report issued on April 22, Bank of America Securities also maintained a Buy rating on the stock with a $860.00 price target.

Bausch + Lomb Corporation (BLCO)

RBC Capital analyst Douglas Miehm maintained a Buy rating on Bausch + Lomb Corporation today and set a price target of $21.00. The company’s shares closed last Wednesday at $15.34.

According to TipRanks.com, Miehm is a 4-star analyst with an average return of 3.9% and a 48.5% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Aurinia Pharmaceuticals, and Pacira Pharmaceuticals. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Bausch + Lomb Corporation with a $18.55 average price target, representing a 15.4% upside. In a report issued on April 24, TipRanks – Google also upgraded the stock to Buy with a $17.50 price target.

Read More on VKTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).